I know Tossa mentioned this but there was no change in liver steatosis which was a primary endpoint (if I am reading the trial details correctly). If you set that as a primary endpoint and don't meet it, isn't that a big problem? How does the FDA look at something like that going forward for a Phase III?
I would be interested in Southoz and rgc68's opinion among others.
- Forums
- ASX - By Stock
- IMC
- predictions?
IMC
immuron limited
Add to My Watchlist
0.00%
!
3.9¢
predictions?, page-23
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
